Scorpius Holdings, Inc. Announces Resignation of Chief Financial Officer

Key Points from the SEC Form 8-K Filing

• Resignation of Chief Financial Officer: On March 29, 2026, Scorpius Holdings, Inc. announced that William Ostrander, the company’s Chief Financial Officer (CFO), notified the company of his decision to resign from his position, effective March 31, 2026.
• No Disagreements with Company Operations: The filing clarifies that Mr. Ostrander did not cite any disagreements with the company regarding its operations, policies, or practices as reasons for his resignation.
• Corporate Details: The company, Scorpius Holdings, Inc., is a Delaware corporation with business operations located at 1305 E. Houston Street, Building 2, San Antonio, TX 78205. The company’s SEC file number is 001-35994 and its Central Index Key (CIK) is 0001476963.
• Emerging Growth Company Status: The filing notes that Scorpius Holdings, Inc. is not classified as an emerging growth company under the SEC’s definitions.
• Filing Details: The report, Form 8-K, was signed and submitted on April 8, 2026, by Jeffrey Wolf, who serves as Chairman, President, and Chief Executive Officer of the company.

Potentially Price-Sensitive Information for Shareholders

• CFO Departure: The resignation of a Chief Financial Officer is a significant corporate event. The CFO is a key executive responsible for the company’s financial strategy, reporting, and stewardship. Any sudden or unexpected departure from this role can trigger investor concern about potential instability in the company’s financial management or future strategic direction.
• Absence of Disputes: It is important to note, and potentially reassuring to investors, that Mr. Ostrander’s resignation was not accompanied by any reported disagreements with company management or policy. This could mitigate speculation about underlying issues within the company’s leadership or governance.
• Leadership Transition Risk: The company has not, in this filing, announced a successor for the CFO role. Prolonged absence or delay in naming a new CFO could lead to uncertainty around the company’s financial oversight and reporting, which may impact investor confidence and share price volatility.

Additional Filing and Company Information

• Company History: The company has previously operated under the names NightHawk Biosciences, Inc. (until May 2, 2022) and Heat Biologics, Inc. (until November 17, 2009).
• Regulatory Compliance: The Form 8-K discloses that the company is fully compliant with all SEC reporting requirements and has not checked any boxes indicating written communications, soliciting material, or pre-commencement tender offer communications. This suggests the filing is solely related to the CFO departure and not any merger or acquisition activity.
• Signatory: The filing is properly authorized and signed by Jeffrey Wolf, reinforcing the legitimacy and accuracy of the report.

Investor Takeaways

• The resignation of a Chief Financial Officer is always a noteworthy event and could move the share price, especially if investors speculate about the reasons or anticipate challenges during the transition.
• The absence of reported disagreements or conflicts may help to calm concerns about internal disputes, but the lack of information about a replacement may introduce some interim uncertainty.
• Investors should monitor forthcoming announcements from Scorpius Holdings, Inc. regarding the appointment of a new CFO or any further explanation about the leadership change.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions. The author and publisher assume no liability for any actions taken based on the information provided above.

View Scorpius Holdings, Inc. Historical chart here